Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin.
Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin.
复制标题
肝癌抗体疗法的进展：侧重于Glypican-3和间皮素。
DOI：
10.2165/11595360-000000000-00000
复制
发表时间：
2011-10-01
期刊：
影响因子：
--
通讯作者：
Ho M
中科院分区：
文献类型：
--
作者：
Ho M
Liver cancer is one of the most common malignancies worldwide. Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) are the two most common primary liver cancers, yet there have been no significant advances in effective therapeutics. There is an urgent need to identify molecular targets for the development of novel therapeutic approaches. In this review, glypican-3 (GPC3) and mesothelin are discussed, with a focus on their potential as targets for antibody therapy in liver cancer. GPC3 and mesothelin are glycosylphosphatidylinositol-anchored proteins present on the cell surface. They are attractive candidates for liver cancer therapy given that GPC3 and mesothelin show high expression in HCC and CCA, respectively. Antibody drugs targeting GPC3 or mesothelin have shown anti-cancer activity in mice. Humanized or chimeric IgG molecules based on first-generation murine monoclonal antibodies against these antigens are being evaluated in clinical studies. Recently, fully human monoclonal antibodies against GPC3 and mesothelin have been isolated by antibody phage display technology that may provide opportunities for novel cancer therapy.
登录
查看更多内容
影响因子：
5.7
作者：
Feng Y;Xiao X;Zhu Z;Streaker E;Ho M;Pastan I;Dimitrov DS
通讯作者：
Dimitrov DS
影响因子：
4.7
作者：
Cheng W;Tseng CJ;Lin TT;Cheng I;Pan HW;Hsu HC;Lee YM
通讯作者：
Lee YM
影响因子：
11.8
作者：
Capurro, Mariana I.;Xu, Ping;Filmus, Jorge
通讯作者：
Filmus, Jorge
DOI：
10.1073/pnas.95.2.669
发表时间：
1998-01-20
影响因子：
11.1
作者：
Chowdhury, PS;Viner, JL;Pastan, I
通讯作者：
Pastan, I
影响因子：
5.2
作者：
Bharadwaj, Uddalak;Li, Min;Yao, Qizhi
通讯作者：
Yao, Qizhi